Canbi Pharma Tech Limited

What are the challenges in formulating excipients for inhalable drugs?

Jun 05, 2025

Hey there! As an excipient supplier, I've been knee - deep in the world of inhalable drugs. It's a fascinating field, but boy, is it full of challenges when it comes to formulating excipients for these drugs. In this blog, I'm gonna break down some of the major hurdles we face.

Compatibility with Active Pharmaceutical Ingredients (APIs)

One of the biggest headaches is ensuring that the excipients we supply are compatible with the active pharmaceutical ingredients. Inhalable drugs often have very specific chemical and physical properties. The API might be sensitive to heat, moisture, or certain chemical reactions.

PCBTh-co-ThSHSNP25-1

For example, some APIs are prone to oxidation. If the excipient we use has any substances that can catalyze oxidation, it can degrade the API over time. This not only reduces the effectiveness of the drug but can also lead to the formation of potentially harmful by - products. We need to conduct a ton of compatibility tests. We're talking about long - term stability studies, where we expose the API - excipient mixture to different environmental conditions like high temperature, high humidity, and light.

We also have to consider the pH of the formulation. Many APIs are stable within a certain pH range. If the excipient changes the pH of the inhalable drug formulation, it can cause the API to precipitate or lose its activity. This is where our expertise comes in. We have to carefully select excipients that won't mess with the API's stability. For instance, Pcbth - co - thaa is one of our excipients that we've designed to have a neutral pH and high chemical stability, which makes it a great candidate for many inhalable drug formulations.

Particle Size and Aerodynamic Properties

Inhalable drugs are all about getting the right particles to the right place in the lungs. The particle size of the excipient - API mixture is crucial. If the particles are too large, they'll get trapped in the upper respiratory tract and won't reach the lungs where they're needed. On the other hand, if they're too small, they might just get exhaled out before they can do their job.

We need to control the particle size distribution very precisely. This involves using advanced manufacturing techniques like micronization or spray - drying. But these processes aren't always straightforward. There are a lot of variables that can affect the final particle size, such as the temperature, pressure, and flow rate during the manufacturing process.

The aerodynamic properties of the particles are also important. We want the particles to have good flowability so that they can be easily delivered from the inhaler device. If the particles clump together, it can block the inhaler and make it difficult for the patient to get the right dose. Our Pcbth - co - thsh excipient has been engineered to have excellent flow properties, which helps in ensuring a consistent and reliable dose delivery.

Regulatory Requirements

The regulatory landscape for inhalable drugs is pretty strict, and for good reason. The safety and efficacy of these drugs are directly related to the quality of the excipients used. Regulatory agencies like the FDA in the United States and the EMA in Europe have very specific guidelines for excipient use in inhalable drug formulations.

We have to make sure that all our excipients meet the required purity standards. There are limits on impurities like heavy metals, microbial contaminants, and residual solvents. We need to have a comprehensive quality control system in place to test for these impurities at every stage of production.

Documentation is also a huge part of regulatory compliance. We have to keep detailed records of the manufacturing process, the raw materials used, and the testing results. This documentation is used to prove that our excipients are safe and suitable for use in inhalable drug formulations. For example, Snp25 - 1 has a detailed set of documentation that shows its compliance with all the major regulatory requirements.

Device Compatibility

Inhalable drugs are delivered using various devices like metered - dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. Each device has its own requirements when it comes to the excipient formulation.

MDIs often use propellants, and the excipient has to be compatible with these propellants. If the excipient reacts with the propellant, it can cause problems like valve blockage or inconsistent dosing. DPIs, on the other hand, rely on the patient's inhalation force to disperse the powder. The excipient has to be formulated in a way that allows for easy dispersion and flow within the device.

Nebulizers convert the drug solution or suspension into an aerosol. The excipient has to be soluble or well - dispersed in the liquid medium and should not clog the nebulizer's nozzle. We have to work closely with device manufacturers to ensure that our excipients are compatible with their devices. This often involves a lot of testing and fine - tuning of the formulation.

Patient - Related Factors

Finally, we can't forget about the patients. The taste and odor of the inhalable drug can have a big impact on patient compliance. If the drug tastes bad or has a strong odor, patients may be less likely to use it as prescribed.

We have to find ways to mask the unpleasant taste and odor of the API without compromising its stability or efficacy. This is where some of our specialty excipients come in. We can use flavoring agents or odor - masking compounds to make the drug more palatable.

We also have to consider the ease of use for patients. The inhaler device should be easy to operate, and the excipient formulation should be stable enough so that the drug doesn't require a lot of special handling.

In conclusion, formulating excipients for inhalable drugs is a complex process that involves dealing with compatibility issues, particle size control, regulatory requirements, device compatibility, and patient - related factors. But that's where we come in as an excipient supplier. We have the knowledge, expertise, and resources to overcome these challenges and provide high - quality excipients for the inhalable drug industry.

If you're in the business of developing inhalable drugs and are looking for reliable excipient suppliers, we'd love to have a chat. We can work together to find the best excipient solutions for your specific needs. Whether it's formulating a new drug or improving an existing one, we're here to help.

References

  • Gupta, R. K., & Banga, A. K. (2017). Inhalation drug delivery: Advances in formulation and device technology. Journal of Controlled Release, 263, 1 - 15.
  • Patton, J. S., & Byron, P. R. (2007). Aerosolized medications: Physical and biological factors in delivery and targeting. Annual Review of Biomedical Engineering, 9, 43 - 70.
  • International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2019). Q3C (R7) Impurities: Guideline for Residual Solvents.
goTop